动物镇静剂市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球动物镇静剂市场价值为 1.674 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 6.5%，这得益于对先进兽医护理和创新动物保健解决方案的需求激增。随着全球范围内宠物收养数量的不断增加，尤其是在城市地区，宠物主人对宠物的健康越来越积极主动，寻求高品质的治疗方案，包括安全有效的镇静剂。人们对动物健康、压力管理和行为控制的认识不断提高，推动了对有助于在手术、运输和梳理过程中使动物平静的镇静剂的需求。

此外，为了满足对肉类和动物性食品日益增长的需求，畜牧业产量显着增加，在医疗检查、手术和运输过程中处理农场动物的有效镇静方法的需求也得到了显着的重视。兽医专业人士也强调了无压力处理和精确诊断的重要性，这导致接受手术、牙齿清洁和诊断成像的动物数量增加，而这些治疗通常都需要镇静。伴侣动物中关节炎和癌症等慢性疾病的发生率不断上升，使得它们需要频繁地去看兽医并接受治疗，这进一步促进了动物镇静剂的使用。兽医基础设施和研究方面的投资不断增加，以及镇静剂配方的技术进步，正在促进全球市场的成长，使动物镇静成为现代兽医实践的重要组成部分。

市场按药物类别细分为吩噻嗪类、α-2 肾上腺素受体激动剂、苯二氮平类、丁酰苯类和其他类别。其中，吩噻嗪类药物成为领先细分市场，2024 年销售额达 6,600 万美元，并因其广泛的应用范围而继续占据主导地位。兽医普遍倾向于使用吩噻嗪类药物进行麻醉前镇静、行为控制以及在运输或梳理等紧张环境中缓解动物的痛苦。吩噻嗪类药物有口服和注射两种形式，具有灵活性和便利性，使其成为兽医专业人士和宠物主人治疗伴侣动物和牲畜的首选。它们已被证实能够镇静动物，且没有明显的副作用，这使得它们成为市场上最值得信赖的镇静剂之一。

根据给药途径，市场分为口服和肠外给药部分。预计 2025 年至 2034 年期间肠外给药领域的复合年增长率将达到 6.3%，仍然是紧急手术、手术和诊断干预期间快速镇静的首选。肠外镇静剂对于确保立即产生镇静效果至关重要，对于执行需要动物保持静止和无压力的复杂程序的兽医来说，它们是必不可少的。

2024 年北美动物镇静剂市场价值为 6,780 万美元，这主要归功于该地区先进的兽医基础设施以及对动物健康和福祉的日益关注。随着兽医护理变得越来越复杂，诊断和外科手术干预的数量不断增加，对安全有效的镇静剂的需求持续上升。宠物主人和牲畜管理者都将动物的舒适度和安全放在首位，因此兽医实践中需要可靠的镇静选择。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 宠物拥有量增加
    • 动物外科手术的兴起
    • 动物和人畜共通传染病发生率不断上升
    • 动物保健支出不断增加，兽医产品开发活动的投资不断增加
  • 产业陷阱与挑战
    • 与动物镇静剂相关的副作用
    • 政府对动物镇静剂的批准有严格的规定
    • 缺乏熟练的人才
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按药物类别，2021 - 2034 年

• 主要趋势
• 吩噻嗪类
• α-2肾上腺素受体激动剂
• 苯二氮平类药物
• 丁基苯类
• 其他药物类别

第六章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 肠外
• 口服

第七章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 外科手术
• 诊断程序
• 临床研究
• 其他应用

第八章：市场估计与预测：按动物类型，2021 - 2034 年

• 主要趋势
• 小动物
  • 狗
  • 猫
  • 其他小动物
• 大型动物
  • 牛
  • 马匹
  • 其他大型动物

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Bayer
• Boehringer Ingelheim Animal Health
• Ceva Animal Health
• Chanelle Pharma
• Dechra Pharmaceuticals
• Elanco Animal Health Incorporated
• Jurox Pty Limited
• Orion Corporation
• Virbac
• Zoetis

The Global Animal Sedatives Market was valued at USD 167.4 million in 2024 and is projected to grow at a CAGR of 6.5% between 2025 and 2034, driven by the surging demand for advanced veterinary care and innovative animal healthcare solutions. As pet adoption continues to rise worldwide, particularly in urban settings, owners are becoming increasingly proactive about their pets' health, seeking high-quality treatment options, including safe and effective sedatives. Growing awareness about animal wellness, stress management, and behavioral control is fueling the demand for sedatives that aid in calming animals during procedures, transportation, and grooming.

Additionally, with a notable increase in livestock production to meet the escalating demand for meat and animal-based food products, the requirement for effective sedation methods to handle farm animals during medical examinations, surgeries, and transportation has gained significant traction. Veterinary professionals are also emphasizing the importance of stress-free handling and precise diagnosis, which has led to a higher number of animals undergoing surgeries, dental cleanings, and diagnostic imaging, all of which often require sedation. The rising prevalence of chronic diseases among companion animals, including arthritis and cancer, necessitates frequent veterinary visits and treatments, further bolstering the use of animal sedatives. Increasing investments in veterinary infrastructure and research, along with technological advancements in sedative formulations, are contributing to market growth globally, making animal sedation an essential component of modern veterinary practices.

The market is segmented by drug class into phenothiazines, alpha-2 adrenergic receptor agonists, benzodiazepines, butyrophenones, and other categories. Among these, phenothiazines emerged as the leading segment, generating USD 66 million in 2024, and continue to dominate due to their wide range of applications. Veterinarians widely prefer phenothiazines for pre-anesthetic sedation, behavioral control, and easing animals in stressful environments such as transport or grooming sessions. Available in both oral and injectable forms, phenothiazines offer flexibility and convenience, making them a top choice among veterinary professionals and pet owners for both companion animals and livestock. Their proven efficacy in calming animals without significant side effects makes them one of the most trusted sedative classes in the market.

Based on route of administration, the market is bifurcated into oral and parenteral segments. The parenteral segment, anticipated to grow at a CAGR of 6.3% during 2025-2034, remains the preferred choice for fast-acting sedation during emergency procedures, surgeries, and diagnostic interventions. Parenteral sedatives are critical in ensuring immediate calming effects, making them indispensable for veterinarians performing complex procedures that require animals to remain still and stress-free.

North America Animal Sedatives Market was valued at USD 67.8 million in 2024, largely due to the region's advanced veterinary infrastructure and increasing focus on animal health and welfare. As veterinary care becomes more sophisticated, with a growing number of diagnostic and surgical interventions, the demand for safe and effective sedatives continues to rise. Pet owners and livestock managers alike are prioritizing animal comfort and safety, driving the need for reliable sedation options in veterinary practices.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership
    • 3.2.1.2 Rising surgical procedures in animals
    • 3.2.1.3 Increasing incidences of animal and zoonotic diseases
    • 3.2.1.4 Increasing animal healthcare expenditure & growing investment in veterinary product development activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with animal sedatives
    • 3.2.2.2 Stringent government regulation for approval of animal sedatives
    • 3.2.2.3 Lack of skilled personnels
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Phenothiazines
• 5.3 Alpha-2 adrenergic receptor agonist
• 5.4 Benzodiazepines
• 5.5 Butyrophenones
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Surgical procedures
• 7.3 Diagnostic procedures
• 7.4 Clinical research studies
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Small animals
  • 8.2.1 Dogs
  • 8.2.2 Cats
  • 8.2.3 Other small animals
• 8.3 Large animals
  • 8.3.1 Cattle
  • 8.3.2 Horses
  • 8.3.3 Other large animals

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Bayer
• 10.2 Boehringer Ingelheim Animal Health
• 10.3 Ceva Animal Health
• 10.4 Chanelle Pharma
• 10.5 Dechra Pharmaceuticals
• 10.6 Elanco Animal Health Incorporated
• 10.7 Jurox Pty Limited
• 10.8 Orion Corporation
• 10.9 Virbac
• 10.10 Zoetis